Linagliptin for heart protection in breast cancer treatment
Treatments studied
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial tests whether taking linagliptin, a diabetes medicine, can help protect the heart during chemotherapy with doxorubicin. It might reduce the risk of heart damage caused by this chemo drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You are an Egyptian citizen.
- You have been diagnosed with breast cancer (confirmed by biopsy).
- Your treatment plan includes chemotherapy with doxorubicin.
- Your doctor has confirmed your heart is healthy enough (heart function is 53% or higher).
- You have not had anthracycline chemotherapy before.
- You can take oral medication and are willing to attend study visits and undergo heart tests.
- You have no significant heart, kidney, liver, or other active health conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called sotagliflozin, typically used for diabetes, can protect the heart during chemotherapy for lymphoma. It may help prevent heart problems that can be a side effect of the cancer treatment.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
This trial tests whether empagliflozin, a diabetes drug, can protect the heart from damage caused by doxorubicin chemotherapy in women with breast cancer. If you are starting this treatment, taking empagliflozin might help keep your heart healthy during and after chemotherapy.
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.